Guided Therapeutics Stock Performance
| GTHP Stock | USD 0.40 0.05 14.29% |
Guided Therapeutics holds a performance score of 10 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.97, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Guided Therapeutics will likely underperform. Use Guided Therapeutics total risk alpha and the relationship between the potential upside and day typical price , to analyze future returns on Guided Therapeutics.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Guided Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile technical indicators, Guided Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 182 K | |
| Total Cashflows From Investing Activities | -14 K |
Guided |
Guided Therapeutics Relative Risk vs. Return Landscape
If you would invest 23.00 in Guided Therapeutics on November 22, 2025 and sell it today you would earn a total of 17.00 from holding Guided Therapeutics or generate 73.91% return on investment over 90 days. Guided Therapeutics is currently generating 1.6137% in daily expected returns and assumes 12.0845% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Guided, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Guided Therapeutics Target Price Odds to finish over Current Price
The tendency of Guided OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.40 | 90 days | 0.40 | about 26.3 |
Based on a normal probability distribution, the odds of Guided Therapeutics to move above the current price in 90 days from now is about 26.3 (This Guided Therapeutics probability density function shows the probability of Guided OTC Stock to fall within a particular range of prices over 90 days) .
Guided Therapeutics Price Density |
| Price |
Predictive Modules for Guided Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Guided Therapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Guided Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Guided Therapeutics is not an exception. The market had few large corrections towards the Guided Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Guided Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Guided Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.49 | |
β | Beta against Dow Jones | 1.97 | |
σ | Overall volatility | 0.09 | |
Ir | Information ratio | 0.12 |
Guided Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Guided Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Guided Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Guided Therapeutics is way too risky over 90 days horizon | |
| Guided Therapeutics has some characteristics of a very speculative penny stock | |
| Guided Therapeutics appears to be risky and price may revert if volatility continues | |
| Guided Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Guided Therapeutics currently holds 1.43 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Guided Therapeutics has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Guided Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Guided Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guided Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guided to invest in growth at high rates of return. When we think about Guided Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 81 K. Net Loss for the year was (2.07 M) with profit before overhead, payroll, taxes, and interest of 20 K. | |
| Guided Therapeutics currently holds about 446 K in cash with (1.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 40.0% of Guided Therapeutics shares are held by company insiders |
Guided Therapeutics Fundamentals Growth
Guided OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Guided Therapeutics, and Guided Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Guided OTC Stock performance.
| Return On Asset | -0.63 | |||
| Operating Margin | (38.63) % | |||
| Current Valuation | 19.66 M | |||
| Shares Outstanding | 48.58 M | |||
| Price To Earning | 36.67 X | |||
| Price To Sales | 219.47 X | |||
| Revenue | 81 K | |||
| EBITDA | (837 K) | |||
| Cash And Equivalents | 446 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.43 M | |||
| Debt To Equity | 0.60 % | |||
| Book Value Per Share | (0.13) X | |||
| Cash Flow From Operations | (1.59 M) | |||
| Earnings Per Share | (0.19) X | |||
| Total Asset | 2.04 M | |||
| Retained Earnings | (125.47 M) | |||
| Current Asset | 1.86 M | |||
| Current Liabilities | 8.55 M | |||
About Guided Therapeutics Performance
Assessing Guided Therapeutics' fundamental ratios provides investors with valuable insights into Guided Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Guided Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia. Guided Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 5 people.Things to note about Guided Therapeutics performance evaluation
Checking the ongoing alerts about Guided Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Guided Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Guided Therapeutics is way too risky over 90 days horizon | |
| Guided Therapeutics has some characteristics of a very speculative penny stock | |
| Guided Therapeutics appears to be risky and price may revert if volatility continues | |
| Guided Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Guided Therapeutics currently holds 1.43 M in liabilities with Debt to Equity (D/E) ratio of 0.6, which is about average as compared to similar companies. Guided Therapeutics has a current ratio of 0.18, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Guided Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Guided Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Guided Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Guided to invest in growth at high rates of return. When we think about Guided Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 81 K. Net Loss for the year was (2.07 M) with profit before overhead, payroll, taxes, and interest of 20 K. | |
| Guided Therapeutics currently holds about 446 K in cash with (1.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 40.0% of Guided Therapeutics shares are held by company insiders |
- Analyzing Guided Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Guided Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Guided Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Guided Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Guided Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Guided Therapeutics' otc stock. These opinions can provide insight into Guided Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Guided OTC Stock Analysis
When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.